[go: up one dir, main page]

PL3044229T3 - Peptydy do zastosowania w leczeniu zapalenia błony śluzowej jamy ustnej - Google Patents

Peptydy do zastosowania w leczeniu zapalenia błony śluzowej jamy ustnej

Info

Publication number
PL3044229T3
PL3044229T3 PL14844276.7T PL14844276T PL3044229T3 PL 3044229 T3 PL3044229 T3 PL 3044229T3 PL 14844276 T PL14844276 T PL 14844276T PL 3044229 T3 PL3044229 T3 PL 3044229T3
Authority
PL
Poland
Prior art keywords
peptides
treatment
oral mucositis
mucositis
oral
Prior art date
Application number
PL14844276.7T
Other languages
English (en)
Inventor
Oreola Donini
Annett Rozek
Jackson Lee
John North
Michael Abrams
Original Assignee
Soligenix, Inc.
Oreola Donini
Annett Rozek
Jackson Lee
John North
Abrams, Michael J.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soligenix, Inc., Oreola Donini, Annett Rozek, Jackson Lee, John North, Abrams, Michael J. filed Critical Soligenix, Inc.
Publication of PL3044229T3 publication Critical patent/PL3044229T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1019Tetrapeptides with the first amino acid being basic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL14844276.7T 2013-09-13 2014-08-11 Peptydy do zastosowania w leczeniu zapalenia błony śluzowej jamy ustnej PL3044229T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361877767P 2013-09-13 2013-09-13
PCT/US2014/050516 WO2015038264A1 (en) 2013-09-13 2014-08-11 Novel peptides and analogs for use in the treatment of oral mucositis

Publications (1)

Publication Number Publication Date
PL3044229T3 true PL3044229T3 (pl) 2024-03-25

Family

ID=52666140

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14844276.7T PL3044229T3 (pl) 2013-09-13 2014-08-11 Peptydy do zastosowania w leczeniu zapalenia błony śluzowej jamy ustnej

Country Status (24)

Country Link
US (2) US9850279B2 (pl)
EP (1) EP3044229B1 (pl)
JP (2) JP6645968B2 (pl)
KR (3) KR102483333B1 (pl)
CN (1) CN105722852B (pl)
AU (3) AU2014318247B2 (pl)
BR (1) BR112016005557B1 (pl)
CA (1) CA2923553C (pl)
DK (1) DK3044229T3 (pl)
ES (1) ES2965906T3 (pl)
FI (1) FI3044229T3 (pl)
HR (1) HRP20231652T1 (pl)
HU (1) HUE066502T2 (pl)
IL (1) IL244573B (pl)
LT (1) LT3044229T (pl)
MX (1) MX382364B (pl)
MY (1) MY177930A (pl)
NZ (2) NZ756128A (pl)
PL (1) PL3044229T3 (pl)
PT (1) PT3044229T (pl)
RU (1) RU2668963C2 (pl)
SG (1) SG11201601891XA (pl)
WO (1) WO2015038264A1 (pl)
ZA (2) ZA201601967B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9808438B2 (en) * 2015-11-09 2017-11-07 Enzychem Lifesciences Corporation Method for treating mucositis
GB201711183D0 (en) 2017-07-12 2017-08-23 Smith & Nephew Antimicrobial or wound care materials, devices and uses
MX2020008803A (es) 2018-02-23 2021-01-15 H Lee Moffitt Cancer Ct & Res Receptores de antígenos quiméricos que se unen a cd83.
US20200108098A1 (en) * 2018-02-23 2020-04-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Anti-cd83 chimeric antigen receptor expressing t regulatory cells
KR102192471B1 (ko) * 2019-10-18 2020-12-17 주식회사 인코스팜 탈모 완화 및 모발 성장을 촉진시키는 펩타이드 및 이를 포함하는 화장료 조성물
EP4221737A1 (en) 2020-09-30 2023-08-09 Biotempt B.V. Autophagy-inhibiting peptide and organic acid salt thereof addressing issues of vascular permeability
US20250064890A1 (en) 2021-08-30 2025-02-27 Unichem Laboratories Limited Protein compositions for the treatment of inflammatory diseases
CN115944708B (zh) * 2021-12-28 2025-02-21 四川好医生攀西药业有限责任公司 三肽在制备治疗和/或预防黏膜或皮肤损伤药物中的应用
US20250195604A1 (en) * 2023-11-27 2025-06-19 Soligenix, Inc. Compositions and Methods of Treatment of Certain Vasculitis Syndromes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2701281B2 (ja) * 1988-01-22 1998-01-21 吉富製薬株式会社 ピラゾロピリジン化合物
US20030162706A1 (en) * 2002-02-08 2003-08-28 The Procter & Gamble Company Angiogenesis modulating proteins
IL163718A0 (en) * 2002-02-26 2005-12-18 Ngstat Medical Corp Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy
CN1269837C (zh) 2002-09-02 2006-08-16 上海高科联合生物技术研发有限公司 一组合成抗菌肽
RU2507213C2 (ru) 2005-10-04 2014-02-20 Солидженикс, Инк., Новые пептиды для лечения и профилактики иммунопатологических заболеваний, включая лечение и профилактику инфекции посредством модулирования врожденного иммунитета
WO2008143679A2 (en) 2006-06-01 2008-11-27 Verenium Corporation Nucleic acids and proteins and methods for making and using them
JP2010505395A (ja) * 2006-10-04 2010-02-25 イニメックス ファーマシューティカルズ インコーポレイテッド 先天免疫を調節することによる感染の処置および予防を含む、免疫関連疾患障害の処置および予防のための新規ペプチド
CN101578368A (zh) * 2006-10-04 2009-11-11 伊尼梅克斯制药公司 包括通过调节先天免疫治疗和预防感染在内的治疗和预防免疫相关疾病的新型肽
EP2373160B1 (en) * 2008-12-08 2017-10-25 Soligenix, Inc. Topically active steroids for use in radiation injury
BRPI1013179A2 (pt) * 2009-03-30 2019-09-24 Prometheus Laboratories Inc peptídeo sintético, métodos para detectar um anticorpo de proteína anti-citrulinado em uma amostra biológica, para realizar um ensaio para ajudar no diagnóstico ou prognóstico de artrite reumatóide, para melhorar a sensibilidade de diagnosticar ou prognosticar artrite reumatóide, ensaio para diagnosticar ou prognosticar artrite reumatóide, kit, e, método para identificar um peptídeo que é imunologicamente reativo com um anticorpo de proteína anti-citrulinado
CN102286073B (zh) * 2011-06-27 2013-09-11 华中科技大学同济医学院附属同济医院 一种与牙釉质表面轴向特异性结合的七肽及其应用
US20150148304A1 (en) * 2013-10-24 2015-05-28 Soligenix, Inc. Novel Peptides and Analogs for Use in the Treatment of Macrophage Activation Syndrome
KR101742069B1 (ko) * 2013-10-25 2017-05-31 (주)연우 리필이 가능한 압출식 앰플용기

Also Published As

Publication number Publication date
HK1221960A1 (zh) 2017-06-16
CN105722852A (zh) 2016-06-29
JP2016531145A (ja) 2016-10-06
CA2923553C (en) 2023-05-23
AU2018214160B2 (en) 2020-07-02
AU2014318247B2 (en) 2018-05-24
JP6645968B2 (ja) 2020-02-14
FI3044229T3 (fi) 2023-12-14
IL244573B (en) 2020-06-30
WO2015038264A1 (en) 2015-03-19
BR112016005557B1 (pt) 2024-01-02
DK3044229T3 (da) 2023-12-18
NZ718534A (en) 2019-09-27
MX382364B (es) 2025-03-11
JP2019142910A (ja) 2019-08-29
LT3044229T (lt) 2024-01-25
ES2965906T3 (es) 2024-04-17
AU2014318247A1 (en) 2016-04-28
MX2016003092A (es) 2016-11-14
HRP20231652T1 (hr) 2024-05-10
HUE066502T2 (hu) 2024-08-28
KR20160058845A (ko) 2016-05-25
ZA202209308B (en) 2023-12-20
KR102304906B1 (ko) 2021-09-24
SG11201601891XA (en) 2016-04-28
ZA201601967B (en) 2023-01-25
RU2016110153A3 (pl) 2018-03-19
PT3044229T (pt) 2023-12-11
CA2923553A1 (en) 2015-03-19
EP3044229B1 (en) 2023-10-04
KR20210042417A (ko) 2021-04-19
CN105722852B (zh) 2021-03-05
BR112016005557A2 (pt) 2017-09-12
IL244573A0 (en) 2016-04-21
KR20210117355A (ko) 2021-09-28
EP3044229A1 (en) 2016-07-20
US20180170964A1 (en) 2018-06-21
AU2020203410A1 (en) 2020-06-11
US9850279B2 (en) 2017-12-26
RU2016110153A (ru) 2017-10-16
MY177930A (en) 2020-09-28
KR102483333B1 (ko) 2022-12-29
NZ756128A (en) 2022-01-28
EP3044229A4 (en) 2017-04-19
RU2668963C2 (ru) 2018-10-05
AU2018214160A1 (en) 2018-08-30
US10253068B2 (en) 2019-04-09
US20160229890A1 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
IL245744A0 (en) Therapeutic peptides
GB201320729D0 (en) Therapeutic compounds and their use
SG10201709090UA (en) Sobetirome in the treatment of myelination diseases
SG11201506766PA (en) Therapeutic peptides
SG11201508469YA (en) Therapeutic peptides
LT3044229T (lt) Peptidai, skirti panaudoti gydant burnos mukozitą
GB201307238D0 (en) Hair treatment kit
GB201311361D0 (en) Compounds and their therapeutic use
SG11201510021TA (en) Compositions and methods for use in medical diagnosis
IL240701A0 (en) kntc2 peptides and components containing them
ZA201508050B (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
SG11201510713VA (en) Dental treatment device
GB201404355D0 (en) Improvements in surgical instruments
PL2943215T3 (pl) Peptydy pochodzące z laktoferycyny do zastosowania w leczeniu nowotworu
SG11201508529RA (en) Skin cleansing composition
GB201308736D0 (en) Compounds and their therapeutic use
GB201307872D0 (en) Medical use
GB201320506D0 (en) Cyclic amino compounds for the use in the treatment of cardiac disorders
GB201302954D0 (en) Dental instrument
GB201314623D0 (en) Novel mucinase for use in therapy or prophylaxis
GB201319004D0 (en) Medical use
GB201311290D0 (en) Medical use
GB201317804D0 (en) Therapeutic compounds and their use
GB201316173D0 (en) Compounds and their therapeutic use
GB201307677D0 (en) Compounds and their therapeutic use